-
REMSleep auditor resigns; company reviewing Q2 2026 financials for possible restatement
Fruci & Associates II resigned as auditor on July 17, 2026; no disagreements cited.
-
RemSleep Holdings changes control; new management team with restricted powers
1000152403 ONTARIO INC acquired ~80% preferred share control from Roman Wood and ~20% from Anita Michaels via private transactions; assumed ~$300K debt.
-
Founder Thomas Wood dies; board names Anita Michaels Chairman, Jeffrey Marshall CEO
Founder, Chairman, and CEO Thomas Wood died on Feb. 26, 2026; he was the creator of DeltaWave® Nasal Pillow System.
-
Remsleep Holdings receives FDA 510(k) clearance for Deltawave CPAP Pillows Interface Mask
FDA granted 510(k) clearance for the Deltawave CPAP Pillows Interface Mask on July 2, 2024.
-
Remsleep Holdings enters equity line with Quick Capital for up to 300M shares at 70% discount
Purchase agreement allows Remsleep to sell up to $100,000 per put (min $20,000) at 70% of lowest traded price over 15-day valuation period.
-
Remsleep Holdings enters equity line with Janbella for up to 300M shares at 70% market discount
Purchase agreement with Janbella Group for up to 300M shares over 18 months (maturity Feb 18, 2025).
-
CEO Thomas Wood receives 2M Series C Preferred shares, gaining 81% voting control, in exchange for IP assignment
Company issued 2,000,000 Series C Preferred shares to CEO Thomas Wood for assignment of all IP related to the business.
-
RemSleep DeltaWave reclassified as implantable by FDA; must resubmit 510K after new testing
FDA reclassified DeltaWave as implantable device; company withdrawing current 510K application.
-
RemSleep reports cytotoxicity test failures on DeltaWave cannula; new lab to retest
Two cytotoxicity tests on DeltaWave cannula MD, Angled Adaptor and Flexible Hose failed in early 2022.